End-to-End Optimization of CAR-T Manufacturing: Boosting Lentiviral Production and T-Cell Transduction with Viral Sensitizer Technology

This poster highlights Virica’s development of next-generation Viral Sensitizer (VSE™) compounds that enhance lentivirus production and T-cell transduction efficiency. Through high-throughput screening, novel VSEs demonstrated multi-fold increases in functional lentivirus yield across adherent and suspension platforms. These compounds also improved T-cell transduction efficiency, achieving equivalent results at lower multiplicities of infection (MOI), reducing vector usage and manufacturing costs. This validates the potential of VSE™ technology to optimize lentiviral-based cell and gene therapy manufacturing.